Supplemental material
Pain Management
Volume 12, 2022 - Issue 3
Research Article
Tanezumab for Chronic low Back Pain: A Long-Term, Randomized, Celecoxib-Controlled Japanese Phase III Safety Study
Shin-ichi Konno1 Department of Orthopaedic Surgery, Fukushima Medical University, Fukushima, 960-1295, Japan
https://orcid.org/0000-0002-2861-2194View further author information
https://orcid.org/0000-0002-2861-2194View further author information, Takuya Nikaido1 Department of Orthopaedic Surgery, Fukushima Medical University, Fukushima, 960-1295, Japanhttps://orcid.org/0000-0002-8162-9294View further author information
https://orcid.org/0000-0002-8162-9294View further author information, John D Markman2 Translational Pain Research Program, Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY 14618, USAhttps://orcid.org/0000-0001-6296-8998View further author information
https://orcid.org/0000-0001-6296-8998View further author information, , , Naoki Isogawa3 Pfizer R&D Japan, Tokyo, 151-8589, Japan;6 Current affiliation: UCB Japan Co., Ltd., Tokyo, 160-0023, Japanhttps://orcid.org/0000-0003-4529-4834View further author information
https://orcid.org/0000-0003-4529-4834View further author information, , Lars Viktrup4 Neuroscience Business Unit, Eli Lilly & Company, Indianapolis, IN 46225, USAhttps://orcid.org/0000-0002-8739-0544View further author information
https://orcid.org/0000-0002-8739-0544View further author information, , Christine R West5 Pfizer Global Product Development, Pfizer Inc., Groton, CT 06340, USAhttps://orcid.org/0000-0001-9447-2911View further author information
https://orcid.org/0000-0001-9447-2911View further author information & show all